Weekly Recap: SPR2015 licensing deal and ifinatamab deruxtecan approval withdrawal

Merck & Co., Inc. (NYSE:MRK) moved aggressively across oncology and ophthalmology—paying $400M upfront for SPR2015 and taking a ~$400M Q3 2026 hit while pausing a US ifinatamab deruxtecan filing, won multiple FDA/Japan approvals and positive Phase 2/3 retinal and PAH data.Previous Week RecapThis is…